Trovafloxacin
Clinical data | |
---|---|
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a605016 |
Routes of administration | Oral, intravenous |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Trovafloxacin (sold as Trovan by
Adverse reactions
Trovafloxacin use is significantly restricted due to its high potential for inducing serious and sometimes fatal liver damage.[2] Currently, the drug is not approved for use in the U.S. or the European Union due to association with cases of acute liver failure and death.
Manufacturing
The key reaction in building the ring consists of
Society and culture
Legal status
The U.S. Food and Drug Administration approved trovafloxacin for therapeutic use in December 1997 for use in patients aged 18 years and older.[4] In June 1999, the agency advised doctors to limit the prescription of trovafloxacin due to adverse events associated with the drug (over 100 cases of acute liver injury reported to FDA). In May 2000, the FDA withdrew marketing authorisation for trovafloxacin.
Trovafloxacin received marketing authorisation in the European Union in October 1998.
Economics
Trovan sales during its first full year on the market contributed US$160 million of Pfizer's total revenue of US$12.6 billion. Investors expected it to eventually bring in US$1 billion per year.[6]
Nigerian clinical trial controversy
In 1996, during a
Between 2002 and 2005 the victims of the Trovan tests in Nigeria filed a
See also
- Alatrofloxacin, a prodrug of trovafloxacin for intravenous administration
- Quinolone
References
- PMID 9124824.
- S2CID 43307678.
- ^ D. Lednicer, The organic chemistry of Drug Synthesis, Vol. 5, p 123 (1995).
- ^ "Trovafloxacin – Approval Letter & Printed Labelling" (PDF). Food and Drug Administration.
- ^ a b c "Public statement on Trovan / Trovan IV / Turvel / Turvel IV: Withdrawal of the marketing authorisations" (PDF). European Medicines Agency.
- ^ a b Petersen M (August 27, 2000). "Unforeseen Side Effects Ruined One Blockbuster". The New York Times. p. 3.11.
- ^ "Suspension of Trovan Drug in Europe Is Urged". The New York Times. June 12, 1999. p. C.3.
- ISBN 9781483350004. Retrieved 2019-01-21.
- ^ Report of the Investigation Committee on the Clinical Trial of Trovafloxacin (Trovan) by Pfizer, Kano, 1996. (PDF), Federal Ministry of Health, Nigeria
- S2CID 1325773.
- PMID 10064255.
- PMID 23240173.
- ^ Stephens J (May 7, 2006). "Panel Faults Pfizer in '96 Clinical Trial In Nigeria". The Washington Post. p. A01. Retrieved 2006-08-28.
- ^ a b Stephens J (July 31, 2009). "Pfizer to Pay $75 Million to Settle Nigerian Trovan Drug-Testing Suit". The Washington Post. Retrieved May 26, 2010.
- ^ Boseley S (9 December 2010). "WikiLeaks cables: Pfizer 'used dirty tricks to avoid clinical trial payout'". The Guardian.
External links
- Abdullahi v Pfizer. US Court of Appeals 2d Cir 30 Jan 2009 Archived 13 June 2011 at the Wayback Machine